Calidi Biotherapeutics, Inc

Contributing Author

Recent Articles by Calidi Biotherapeutics, Inc

Aug-21	Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option CLDI GlobeNewswire
Aug-20	Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering CLDI GlobeNewswire
Aug-08	Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire
Jul-29	Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma CLDI GlobeNewswire
Jul-25	Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 CLDI GlobeNewswire
Jul-22	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 CLDI GlobeNewswire
Jul-10	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment CLDI GlobeNewswire
Jul-09	Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds CLDI GlobeNewswire
Jul-08	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment CLDI GlobeNewswire
Jun-27	Calidi Biotherapeutics Announces Shareholder Letter from CEO CLDI GlobeNewswire
Jun-02	Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting CLDI GlobeNewswire
May-14	Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.